Soluble interleukin-6 receptor to interleukin-6 (sIL-6r/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 861-864

  Terracciano, Daniela ^a   Bruzzese, Dario ^a   Ferro, Matteo ^a   Autorino, Riccardo ^c   di Lorenzo, Giuseppe ^b   Buonerba, Carlo ^b   Mariano, Angela ^a   Macchia, Vincenzo ^a   Altieri, Vincenzo ^a   di Carlo, Angelina ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Gleason upgrading; IL 6; sIL 6R; uPA; uPAR

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

EID: 79960305611     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.337     Document Type: Article

References (25)

1. Mohler JL: The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 8: 145, 2010.
2. Epstein JI: An update of the Gleason grading system. J Urol 183: 433-440, 2010.
3. Moussa AS, Li J, Soriano M, Klein EA, Dong F and Jones JS: Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103: 43-48, 2009.
4. Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, Jeong H, Byun SS, Lee HJ, Choe G and Lee SE: Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol 27: 271-276, 2009.
5. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL and Anderson KC: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159: 2212-2221, 1997.
6. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636, 2000.
7. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML and Lin JT: Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11: 517-527, 2004.
8. Rose-John S: Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 50: 603-611, 2003.
9. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM and Slawin KM: The addition of interleukin-6 soluble receptor and transforming growth factor ß1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21: 3573-3579, 2003.
10. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor ß(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10: 1992-1999, 2004.
11. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM and Karakiewicz PI: Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14: 3785-3791, 2008.
12. Blasi F and Sidenius N: The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584: 1923-1930, 2010.
13. Smith HW and Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36, 2010.
14. Helenius MA, Saramaki OR, Linja MJ, Tammela TL and Visakorpi T: Amplification of urokinase gene in prostate cancer. Cancer Res 61: 5340-5344, 2001.
15. Gavrilov D, Kenzior O, Evans M, Calaluce R and Folk WR: Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 37: 1033-1040, 2001.
16. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM and Slawin KM: Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25: 349-355, 2007.
17. Porter CR, Suardi N, Kodama K, Capitanio U, Gibbons RP, Correa R, Jeldres C, Perrotte P, Montorsi F and Karakiewicz PI: A nomogram predicting metastatic progression after radical prostatectomy. Int J Urol 15: 889-894, 2008.
18. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008-1015, 2001.
19. Spiotto MT and Chung TD: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42: 186-195, 2000.
20. Deeble PD, Murphy DJ, Parsons SJ and Cox ME: Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 8471-8482, 2001.
21. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH and Keller ET: Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66: 3087-3095, 2006.
22. Hong DS, Angelo LS and Kurzrock R: Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 110: 1911-1928, 2007.
23. Ara T and Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231, 2010.
24. Santer FR, Malinowska K, Culig Z and Cavarretta IT: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17: 241-253, 2010.
25. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF and Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268: 160-167, 2001.